Eguchi J, Inomata Y, Yuasa T, Egawa M, Saito K
Pharmaceuticals Laboratory I, Yokohama Research Center, Mitsubishi Chemical Corporation, Japan.
Arzneimittelforschung. 1997 Dec;47(12):1337-47.
This is a first report on the investigation of the antidepressant activity of MCI-225 (4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-d]pyrimidine monohydrate hydrochloride, CAS 99487-26-0) in comparison with maprotiline (CAS 10347-81-6), desipramine (CAS 58-28-6), imipramine (CAS 113-52-0) and trazodone (CAS 25332-39-2). MCI-225 inhibited the synaptosomal uptake of noradrenaline (NA, Ki = 35.0 nmol/l), serotonin (5-HT, Ki = 491 nmol/l), and dopamine (Ki = 14,800 nmol/l), although it did not inhibit MAO-A and MAO-B activities. MCI-225 showed high affinity only for the 5-HT3 receptor (Ki = 81.0 nmol/l) among all receptors tested including M1, M2, alpha 1, and H1 receptors. The inhibition of the von Bezold-Jarisch reflex by MCI-225 (ID50 = 22.2 mg/kg, p.o.) suggests its antagonistic action on the 5-HT3 receptor. MCI-225 dose-dependently reduced reserpine-induced hypothermia (0.3-10 mg/kg, p.o.) and potentiated yohimbine-induced lethality (3-100 mg/kg, p.o.) in mice. These effects of MCI-225 were as potent as desipramine and more potent than maprotiline, imipramine and trazodone. MCI-225 and desipramine did not change either 5-HTP-induced head movements or p-CA-induced hyperactivity in rats. In forced swimming tests in rats, the minimum effective doses of MCI-225, maprotiline, desipramine, and imipramine were 1, 30, 10 and 30 mg/kg, p.o., respectively, for 5-days administration. Only MCI-225 had shown its full activity with this short term treatment. MCI-225 (10 mg/kg, p.o.) decreased the REM sleep period without affecting slow-wave sleep or wakefulness in rats. Even at 100 mg/kg, p.o. MCI-225 and trazodone did not inhibit oxotremorine-induced tremor, lacrimation or salivation in mice in contrast with imipramine. These results suggest that MCI-225, which selectively inhibits NA uptake and antagonizes the 5-HT3 receptor, has potential as a new type of potent antidepressant.
这是关于MCI - 225(4 - (2 - 氟苯基)-6 - 甲基 - 2 - (1 - 哌嗪基)噻吩并[2,3 - d]嘧啶盐酸盐一水合物,CAS 99487 - 26 - 0)与马普替林(CAS 10347 - 81 - 6)、地昔帕明(CAS 58 - 28 - 6)、丙咪嗪(CAS 113 - 52 - 0)和曲唑酮(CAS 25332 - 39 - 2)相比抗抑郁活性研究的首篇报告。MCI - 225抑制去甲肾上腺素(NA,Ki = 35.0 nmol/L)、5 - 羟色胺(5 - HT,Ki = 491 nmol/L)和多巴胺(Ki = 14,800 nmol/L)的突触体摄取,尽管它不抑制单胺氧化酶A(MAO - A)和单胺氧化酶B(MAO - B)的活性。在包括M1、M2、α1和H1受体在内的所有测试受体中,MCI - 225仅对5 - HT3受体显示出高亲和力(Ki = 81.0 nmol/L)。MCI - 225对贝佐尔德 - 雅里什反射的抑制作用(ID50 = 22.2 mg/kg,口服)表明其对5 - HT3受体具有拮抗作用。MCI - 225剂量依赖性地降低小鼠利血平诱导的体温过低(0.3 - 10 mg/kg,口服)并增强育亨宾诱导的致死性(3 - 100 mg/kg,口服)。MCI - 225的这些作用与地昔帕明一样有效,且比马普替林、丙咪嗪和曲唑酮更有效。MCI - 225和地昔帕明均未改变大鼠中5 - 羟色氨酸诱导的头部运动或对 - 香豆酸诱导的多动。在大鼠的强迫游泳试验中,连续5天给药时,MCI - 225、马普替林、地昔帕明和丙咪嗪的最小有效剂量分别为1、30、10和30 mg/kg,口服。仅MCI - 225在这种短期治疗中显示出其全部活性。MCI - 225(10 mg/kg,口服)减少大鼠的快速眼动睡眠期,而不影响慢波睡眠或清醒状态。即使口服剂量达100 mg/kg,与丙咪嗪相比,MCI - 225和曲唑酮也不抑制氧化震颤素诱导的小鼠震颤、流泪或流涎。这些结果表明,选择性抑制NA摄取并拮抗5 - HT3受体的MCI - 225具有作为新型强效抗抑郁药的潜力。